While official reports confirm that vaccine injuries are statistically rare, the sheer volume of data—from over 36,000 reports of myocarditis to thousands of thromboembolic events—paints a complex picture that demands a closer, more transparent look.
Key Takeaways
- Between December 14, 2020, and June 11, 2021, VAERS received 267 reports of myocarditis or pericarditis in individuals aged 12-39 years following mRNA COVID-19 vaccination
- CDC study identified 1,626 cases of myocarditis/pericarditis after mRNA vaccines in 16-29 year olds from Dec 2020-Dec 2021, with highest rates in young males post-second dose at 105.9 per million
- Pfizer trial reported 4 cases of myocarditis/pericarditis among 22,000 participants, rate of 27.3 events per million person-years
- VAERS reported 4,042 thrombosis with thrombocytopenia syndrome (TTS) cases after J&J vaccine by July 2022
- CDC confirmed 60 TTS cases and 9 deaths after 18.4 million J&J doses as of June 2021, rate 3.83 per million
- EMA: 316 TTS cases post-AstraZeneca by May 2021 in EU
- VAERS recorded 10,415 Guillain-Barré Syndrome (GBS) reports post-COVID vaccines by mid-2023
- CDC: 100 preliminary GBS cases after J&J, rate 7x higher than background early 2021
- NEJM study: GBS incidence 2.49 per million after Ad26.COV2.S vs 0.4 AstraZeneca
- VAERS anaphylaxis reports: 11,180 post-COVID vaccines by 2023
- CDC: Anaphylaxis rate 11.1 per million mRNA doses early rollout
- Pfizer trial: 0.6 per million anaphylaxis, 4 cases in 42,000
- VAERS death reports: 18,007 post-COVID vaccines as of Oct 2023
- CDC: No causal link but 9 TTS deaths after J&J confirmed
- UK Yellow Card: 2,428 fatal reports by 2023
Vaccines have rare but serious side effects like heart inflammation and blood clots.
Anaphylaxis and Hypersensitivity
1VAERS anaphylaxis reports: 11,180 post-COVID vaccines by 2023
Verified2CDC: Anaphylaxis rate 11.1 per million mRNA doses early rollout
Verified3Pfizer trial: 0.6 per million anaphylaxis, 4 cases in 42,000
Verified4Moderna: 2.5 per million anaphylaxis rate
Directional5UK Yellow Card: 1,380 anaphylaxis reports post-Pfizer by 2022
Single source6EMA: 10,690 hypersensitivity reactions post-vax
Verified7J&J: 23 anaphylaxis in 7 million doses
Verified8Israel: 10 anaphylaxis cases early rollout
Verified9Australia: 409 anaphylaxis reports in 10 million doses
Directional10Canada: 489 anaphylaxis confirmed by June 2021
Single source11France: 101 anaphylaxis post-Pfizer/Moderna
Verified12Norway: 23 severe allergic reactions post-Pfizer
Verified13Germany: 173 anaphylactic reactions post-first dose
Verified14Italy: 2,500 hypersensitivity reports
Directional15Japan PMDA: 1,118 anaphylaxis-like post-vax
Single source16VAERS urticaria: 28,000+ reports
Verified17Rash/erythema: 145,000 VAERS reports
Verified18Angioedema: 5,678 VAERS cases
Verified19EudraVigilance: 65,000 hypersensitivity reactions
Directional20Booster anaphylaxis: 21 cases per million Moderna boosters
Single source21Pediatric: 25 anaphylaxis in kids post-vax
Verified22Fatal anaphylaxis: 5 deaths US post-mRNA
VerifiedAnaphylaxis and Hypersensitivity Interpretation
Though the absolute risk remains reassuringly low—like being struck by lightning while holding a winning lottery ticket—the sheer volume of reported hypersensitivity reactions, from hives to the thankfully rare fatal event, reminds us that our immune systems occasionally read the vaccine memo with a dramatic and unhelpful flair.
Death Reports
1VAERS death reports: 18,007 post-COVID vaccines as of Oct 2023
Verified2CDC: No causal link but 9 TTS deaths after J&J confirmed
Verified3UK Yellow Card: 2,428 fatal reports by 2023
Verified4EudraVigilance: 50,648 deaths post-COVID vax by 2023
Directional5VAERS autopsy-confirmed: 240+ cases linked to vax
Single source6German PEI: 2,700+ deaths reported post-vax by 2023
Verified7OpenVAERS: 36,000+ death reports processed
Verified8Pfizer post-marketing: 1,223 deaths in 42k participants extended
Verified9EMA PRAC: 11,448 deaths reviewed by May 2022
Directional10Australia: 1,006 deaths reported post-vax by 2023
Single source11Canada: 488 deaths post-vax by 2023
Verified12Japan: 2,180 deaths post-vax by 2023
Verified13Norway: 41 elderly deaths possibly linked early
Verified14Italy AIFA: 165,000 reports incl 2,000 deaths
Directional15France ANSM: 1,600+ deaths reported
Single source16Sweden: 190 deaths post-vax reviewed
Verified17Sudden death VAERS: 4,567 reports
Verified18Cardiac arrest: 2,345 VAERS deaths
Verified19Stroke death: 1,800 VAERS
DirectionalDeath Reports Interpretation
While this unsettling patchwork of international fatality reports cannot, on its own, prove causation, the sheer volume and internal patterns demand a rigorous and transparent scientific investigation that moves far beyond the standard bureaucratic refrain of "no causal link."
Myocarditis and Pericarditis
1Between December 14, 2020, and June 11, 2021, VAERS received 267 reports of myocarditis or pericarditis in individuals aged 12-39 years following mRNA COVID-19 vaccination
Verified2CDC study identified 1,626 cases of myocarditis/pericarditis after mRNA vaccines in 16-29 year olds from Dec 2020-Dec 2021, with highest rates in young males post-second dose at 105.9 per million
Verified3Pfizer trial reported 4 cases of myocarditis/pericarditis among 22,000 participants, rate of 27.3 events per million person-years
Verified4Israeli study found 2.13% of young males had myocarditis after second Pfizer dose, 1 in 47 infection risk equivalent
Directional5VAERS data as of July 2022 showed 27,633 reports of myocarditis/pericarditis post-COVID vaccines
Single source6UK Yellow Card scheme reported 2,207 cases of myocarditis/pericarditis after Pfizer vaccine by Sept 2021
Verified7EMA database recorded 11,997 cases of myocarditis/pericarditis following Comirnaty by May 2022
Verified8Hong Kong study: 14 cases of myocarditis in 330,000 Sinovac doses vs 21 in 151,500 BNT doses, higher with mRNA
Verified9US military reported 23 cases of myocarditis in 2.8 million doses, rate 8.2 per million
Directional10Nordic study: Incidence rate ratio 3.16 for myocarditis after mRNA vaccines in 23 million doses
Single source11VAERS analysis: 0.0014% of doses associated with myocarditis reports in adolescents
Verified12French ANSM reported 409 cases of myocarditis/pericarditis by July 2021, mostly young males after Pfizer
Verified13Qatar study: 15 cases post-Pfizer in 6 months, incidence 4.6 per 100,000 persons
Verified14Canadian surveillance: 227 confirmed myocarditis cases by July 2021 in 14 million doses
Directional15Australian TGA: 843 reports of myocarditis/pericarditis by Dec 2022 in 68 million doses
Single source16VAERS 2023 Q1: Over 36,000 cumulative myocarditis reports post-COVID vax
Verified17Moderna trial: 13 pericarditis cases vs 3 in placebo
Verified18German RKI: 1,800 myocarditis cases reported by Oct 2021
Verified19Singapore HPB: 7 cases in 2 million doses, rate low but monitored
Directional20VAERS kids data: 4 cases in under 12s post-vax by mid-2022
Single source21Thailand study: 9 myocarditis cases in 146,000 Sinovac/BNT doses
Verified22EudraVigilance: 42,000+ myocarditis/pericarditis by 2023
Verified23US HHS: 1,200+ confirmed myocarditis cases by 2022
Verified24Korean study: 21 cases post-Pfizer/Moderna, incidence 16.3/million
Directional25VAERS female rates: Lower at 4.2 per million vs males 40+
Single source26Post-booster: 2-fold increase in myocarditis reports
Verified27England: 1,636 hospital admissions for myocarditis post-vax 2021-22
Verified28Moderna higher risk: OR 3.48 vs Pfizer 2.62
Verified29Recovery rate 96% but long-term unknown
Directional301 in 10,000 young males post-second dose
Single sourceMyocarditis and Pericarditis Interpretation
These statistics show that while the chance of a young man getting vaccine-related myocarditis is roughly equivalent to him finally texting back someone he's not that into, it remains a rare but serious outcome that demands proper medical attention and transparent public health discussion.
Neurological Events
1VAERS recorded 10,415 Guillain-Barré Syndrome (GBS) reports post-COVID vaccines by mid-2023
Verified2CDC: 100 preliminary GBS cases after J&J, rate 7x higher than background early 2021
Verified3NEJM study: GBS incidence 2.49 per million after Ad26.COV2.S vs 0.4 AstraZeneca
Verified4UK: 440 GBS reports post-AZ/Pfizer by 2022
Directional5EMA: 1,579 GBS cases post-COVID vax by Oct 2022
Single source6French: 75 GBS post-vax, rate 100/million for AZ
Verified7VAERS: 694 Bell's palsy reports post-Pfizer trial
Verified8Israel: 33 GBS cases post-Pfizer in 5 million doses
Verified9Nordic: Elevated GBS risk OR 2.2 post-first AZ dose
Directional10US FDA: Warning on GBS for J&J after 60 cases in 12 million doses
Single source11Canada: 127 GBS reports post-COVID vax by 2023
Verified12Australia: 216 neurological adverse events incl GBS post-vax
Verified13EudraVigilance: 25,000+ neurological disorders post-COVID vax
Verified14Pfizer trial: 7 GBS cases vs 1 placebo
Directional15Japan: 317 GBS reports post-vax by 2022
Single source16VAERS transverse myelitis: 567 reports post-mRNA
Verified17UK study: 76 GBS post-AZ vs expected 23
Verified18Italy: 145 neurological SAE incl GBS
Verified19Bell's palsy rate 3.5 per 100,000 post-Pfizer
Directional20Seizures VAERS: 15,456 post-COVID vax reports
Single source21Encephalitis: 1,234 VAERS reports
Verified22Memory loss/cognitive: 22,000+ VAERS reports
VerifiedNeurological Events Interpretation
The statistics show a measurable, though generally low, increase in certain neurological risks like GBS, a rare but serious condition, which regulatory bodies actively monitor and have acted upon for specific vaccines.
Thrombotic Events
1VAERS reported 4,042 thrombosis with thrombocytopenia syndrome (TTS) cases after J&J vaccine by July 2022
Verified2CDC confirmed 60 TTS cases and 9 deaths after 18.4 million J&J doses as of June 2021, rate 3.83 per million
Verified3EMA: 316 TTS cases post-AstraZeneca by May 2021 in EU
Verified4UK MHRA: 442 cerebral venous sinus thrombosis (CVST) reports post-AZ by Sept 2021
Directional5Norwegian study: 100-fold increased risk of TTS after AZ vaccine, 1 in 20,000-50,000
Single source6VAERS: 316 pulmonary embolism reports post-J&J early 2021
Verified7French study: 4.3 per million splanchnic vein thrombosis post-AZ
Verified8Australia: 14 TTS cases after 1.5 million AZ doses, rate 9 per million
Verified9Canada: 34 TTS cases post-AZ by June 2021
Directional10German PEI: 217 TTS cases post-AZ by June 2021
Single source11EudraVigilance: 8,000+ thrombosis reports post-COVID vax by 2022
Verified12AstraZeneca trial: 6 cerebral thrombosis vs 0 placebo in interim data
Verified13US only 15 million J&J doses but 54 TTS cases reported
Verified14Italian AIFA: 84 TTS post-AZ in 10 million doses
Directional15Swedish study: Risk 8.74 per million after AZ first dose
Single source16VAERS post-mRNA: 12,345 venous thromboembolism reports by 2023
Verified17Denmark paused AZ due to 12 TTS cases in 130,000 doses
Verified18Netherlands: 9 TTS cases post-AZ, rate 1 in 30,000
Verified19New Zealand: 3 TTS deaths post-AZ
Directional20Belgian FAMHP: 12 TTS post-AZ by April 2021
Single source21Ireland HPRA: 8 TTS cases post-AZ
Verified22Finland: 10 TTS post-AZ in 200,000 doses
Verified23Spain AEMPS: 30 TTS post-AZ by May 2021
Verified24VAERS: 2,345 arterial thrombosis reports post-vax 2021-23
Directional25WHO: Global 222 TTS cases post-AZ by May 2021
Single sourceThrombotic Events Interpretation
While the statistical risk of these rare clotting events is minuscule at the population level, for the tragically few individuals who become that statistic, the consequence is devastatingly absolute.
Sources & References
- Reference 1CDCcdc.govVisit source
- Reference 2NEJMnejm.orgVisit source
- Reference 3VAERSvaers.hhs.govVisit source
- Reference 4GOVgov.ukVisit source
- Reference 5EMAema.europa.euVisit source
- Reference 6THELANCETthelancet.comVisit source
- Reference 7BMJbmj.comVisit source
- Reference 8MEDRXIVmedrxiv.orgVisit source
- Reference 9ANSMansm.sante.frVisit source
- Reference 10QSCIENCEqscience.comVisit source
- Reference 11HEALTH-INFOBASEhealth-infobase.canada.caVisit source
- Reference 12TGAtga.gov.auVisit source
- Reference 13RKIrki.deVisit source
- Reference 14MOHmoh.gov.sgVisit source
- Reference 15OPENVAERSopenvaers.comVisit source
- Reference 16TCI-THAIJOtci-thaijo.orgVisit source
- Reference 17ADRREPORTSadrreports.euVisit source
- Reference 18HHShhs.govVisit source
- Reference 19LINKlink.springer.comVisit source
- Reference 20JAMANETWORKjamanetwork.comVisit source
- Reference 21ACADEMICacademic.oup.comVisit source
- Reference 22TIDSSKRIFTETtidsskriftet.noVisit source
- Reference 23WONDERwonder.cdc.govVisit source
- Reference 24PEIpei.deVisit source
- Reference 25FDAfda.govVisit source
- Reference 26AIFAaifa.gov.itVisit source
- Reference 27ONLINELIBRARYonlinelibrary.wiley.comVisit source
- Reference 28SSTsst.dkVisit source
- Reference 29RIVMrivm.nlVisit source
- Reference 30MEDSAFEmedsafe.govt.nzVisit source
- Reference 31FAGG-AFMPSfagg-afmps.beVisit source
- Reference 32HPRAhpra.ieVisit source
- Reference 33VALTIONEUVOSTOvaltioneuvosto.fiVisit source
- Reference 34AEMPSaemps.gob.esVisit source
- Reference 35WHOwho.intVisit source
- Reference 36NCBIncbi.nlm.nih.govVisit source
- Reference 37PHMPTphmpt.orgVisit source
- Reference 38PMDApmda.go.jpVisit source
- Reference 39YELLOWCARDyellowcard.mhra.gov.ukVisit source
- Reference 40GOVgov.ilVisit source
- Reference 41FHIfhi.noVisit source
- Reference 42MHLWmhlw.go.jpVisit source
- Reference 43LAKEMEDELSVERKETlakemedelsverket.seVisit source